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Using non-small cell lung carcinoma (NSCLC) cells harboring the erlotinib-sensitizing Epidermal Growth
Factor Receptor (EGFR) exon 19 mutation delE746-A750, we developed erlotinib-refractory derivatives in
which hyperactive Insulin-like Growth Factor-1 Receptor (IGF-1R) signaling associated with enrichment in
epithelial-to-mesenchymal transition (EMT)-related morphological and transcriptional features. We then
explored whether an IGF-1R/EMT crosstalk was sufficient to promote erlotinib refractoriness in the absence
of second-site EGFR mutations, MET and AXL hyperactivation. Transforming Growth Factor-beta1
(TGFb1)-induced mesenchymal trans-differentiation was sufficient to impede erlotinib functioning in the
presence of drug-sensitive delE746-A750 EGFR mutation. Pharmacological blockade of IGF-1R fully
prevented the TGFb1’s ability to activate an EMT protein signature [E-cadherin low/vimentin high]. The
sole presence of erlotinib was capable of rapidly activate an IGF-1R-dependent, vimentin-enriched
mesenchymal-like phenotype in delE746-A750-mutated epithelial cells. Even if transient, NSCLC cells’
intrinsic plasticity to undergo crosstalk between IGF-1R and EMT signaling pathways can sufficiently
eliminate the erlotinib-sensitizing effect of highly prevalent EGFR mutations and suggests the urgent need
for dual IGF-1R/EMT-targeting strategies to circumvent erlotinib resistance.
S
omatic mutations in exons encoding the tyrosine kinase (TK) domain of the epidermal growth factor
receptor (EGFR) are positively associated with increased sensitivity of non-small cell lung cancer
(NSCLC) patients to the selective EGFR TK inhibitors (TKIs) gefitinib (IressaTM) and erlotinib
(TarcevaTM)1–4. Prospective trials have demonstrated an impressive ,75% response rate for patients whose
tumors harbor these mutations5,6, which occur as either multinucleotide in-frame deletions in exon 19 (e.g.,
delE746-A750) or as single missense mutations (e.g., L858R). Unfortunately, the EGFR TKI-driven improvement
in patient outcome is notably limited because virtually all NSCLC patients with erlotinib/gefitinib-sensitizing
EGFR mutations eventually acquire resistance after a median of 6–12 months of EGFR TKI therapy7,8. In
approximately half of cases, the tumor cells present after disease progression contain second-site mutations that
alter drug binding to the EGFR TK domain9–13. The most common lesion (.90%) is the so-called ‘‘gatekeeper
mutation,’’ which involves a substitution of methionine for threonine at position 790 (T790M).
More recently, in addition to other second-site mutations associated with acquired resistance to EGFR TKIs
(e.g., L747S and D761Y in exon 19 or T854A in exon 21), novel EGFR-independent mechanisms have been
discovered that contribute to EGFR TKI resistance either in the absence or presence of the EGFR T790M mutation
reviewed in 14–16. The second well-known mechanism of gefitinib/erlotinib resistance is the MET receptor tyrosine
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HER3-mediated activation of PI3K in the presence of EGFR TKIs17.
Although approximately 60% of MET amplifications are independ-
ent of the T790M mutation, MET amplification and EGFR T790M
are not mutually exclusive; they can be detected in the same resistant
tumor or may occur independently in different metastatic sites in the
same patient17–19; it remains to be unambiguously demonstrated
whether treatment with EGFR TKIs selects for pre-existing cells with
the EGFR T790M mutation and/or MET amplification during the
acquisition of EGFR TKI resistance or whether resistant tumors are
emerged during the treatment.
EGFR T790M and MET amplification, which can be detected in up
to 20% of EGFR NSCLCs secondarily refractory to EGFR TKIs,
account for approximately 60–70% of all known causes of acquired
resistance to gefitinib/erlotinib. Consequently, ongoing research is
attempting to identify the mechanisms that may account for the 30–
40% of EGFR TKI-resistant, EGFR-mutated tumors that do not carry
EGFR mutations or MET amplification. Although increased activa-
tion of insulin-like growth factor-1 receptor (IGF-1R) through the
loss of IGF-binding proteins and loss or reduction of the tumor
suppressor PTEN have been associated with acquired resistance to
EGFR TKIs in laboratory models20–22, these mechanisms have not yet
been validated in specimens from EGFR TKI-refractory patients.
Activation of the AXL RTK through overexpression or upregulation
of the AXL ligand GAS6 confers acquired resistance to erlotinib in
pre-clinical models of EGFR-mutated NSCLCs; AXL is overex-
pressed in ,20% of post-erlotinib-treated patients with EGFR TKI
resistance23. Mutations in PIK3CA have been identified in ,5% of
EGFR-mutant lung cancers with acquired resistance to EGFR TKIs24.
Interestingly, AXL upregulation has been associated with the
development of an epithelial-to-mesenchymal transition (EMT)23.
Similarly, genetic and histological analyses of tumor biopsies from
NSCLCs with acquired resistance to EGFR inhibitors revealed that a
subgroup of resistant carcinomas underwent a pronounced EMT24.
EMT, which has been largely considered a general biological feature
rendering NSCLCs sensitive or insensitive to EGFR inhibition25–28,
has also been associated with acquired resistance to EGFR TKIs in
laboratory models29,30. Development of EMT was observed in a
NSCLC patient who acquired resistance to erlotinib in the absence
of known resistance mechanisms, such as the EGFR T790M mutation
and MET amplification30. In this scenario, it is tempting to suggest
that EMT is a convergent mechanism that might be rapidly selected
to bypass the EGFR pathways in resistant tumors.
Here, using EGFR-mutated PC-9 NSCLC cells, we developed erlo-
tinib-refractory PC-9 derivatives lacking most of the mechanisms of
secondary resistance described to date. We now present proof-of-
concept evidence that in the absence of second-site EGFR mutations,
MET hyperactivation, PI3KCA mutation or activation of AXL, the
stimulation of crosstalk between IGF-1R and EMT signaling path-
ways, even if transient, is sufficient to notably suppress the erlotinib-
sensitizing effect of the highly-prevalent EGFR exon 19 in-frame
deletion mutation in lung carcinoma cells.
Results
PC-9 cells with acquired resistance to erlotinib cross-activate the
insulin-like growth factor-1 receptor IGF-1R. Human EGFR
Pathway qBiomarker Somatic Mutation PCR Arrays, which com-
bine allele-specific amplification and 59 hydrolysis probe detection
to detect as little as 0.01% somatic mutation in a background of wild-
type genomic DNA, were used to assess the status of 85 possible
mutations in the EGFR pathway. The array likewise detected the
erlotinib-sensitizing deletion mutation delE746-A750 in EGFR
exon 19 in parental PC-9 cells. Of note, we failed to detect new co-
occurring mutations in the EGFR pathway when the pooled
populations of PC-9 cells with acquired resistance to erlotinib,
which maintained the same expression level of EGFR delE746-
A750, were profiled in parallel (data not shown).
After excluding the presence of a secondary resistance mutation in
the EGFR gene, we investigated whether aberrant activation of
another RTKs such as MET or AXL, might mediate erlotinib resist-
ance. We took advantage of a low-scale phospho-proteomic
approach to molecularly profile RTKs that might distinctively cor-
relate with PC-9 sensitivity/resistance to erlotinib. To simultaneously
assess the activation status of multiple receptor tyrosine kinases
(RTKs), we employed a commercially available phospho-proteome
assay [Human Phospho-RTK Array Proteome ProfilerTM], which
allows for the rapid, sensitive, and simultaneous detection of 42
RTKs in a single antibody-based microarray. This protein array
technology allows for screening of multiple phospho-proteins with-
out performing numerous immunoprecipitation and/or immuno-
blotting analyses. Erlotinib-responsive PC-9 parental cells and
their erlotinib-refractory PC-9/ErlR derivatives were treated with
erlotinib and then immediately lysed and analyzed for changes in
phosphorylated signaling responses. Because the lysates were col-
lected immediately following erlotinib exposure, the results likely
represent immediate responses by tumor cells to erlotinib. In
untreated PC-9 cells, EGFR (HER1) was the sole highly phosphory-
lated receptor among the four members of the HER network, and this
EGFR phosphorylation was notably decreased in the presence of
erlotinib (Fig. 1A). Phospho-RTK profiling of cell lysates from
untreated PC-9/ErlR POOLs clearly revealed that the constitutive
status of EGFR phosphorylation was mostly unaltered compared
with parental PC-9 cells. PC-9/ErlR POOLs notably displayed an
erlotinib-refractory activation of EGFR accompanied by hyperacti-
vation of the insulin growth factor-1 receptor (IGF-1R) (Fig. 1A).
MET, AXL, and HER2 were among the RTKs tested in the phos-
pho-RTK array; therefore, our results confirmed that acquired
resistance in non-small cell lung cancer cells bearing the erlotinib-
sensitizing deletion mutation delE746-A750 in EGFR exon 19 may
occur in the absence of most of the known mechanisms of secondary
resistance, including second-site EGFR mutations, MET and/or AXL
activation, HER2 amplification or loss of the mutant delE746-A750
EGFR gene itself. By using Human EGFR Pathway qBiomarker
Somatic Mutation PCR Arrays we confirmed also that acquired res-
istance to erlotinib took place in the absence of secondary BRAF and/
or NRAS mutations (data not shown).
Pharmacological inhibition of IGF-1R activity circumvents acquired
resistance to erlotinib. The above results strongly suggested that EGFR
and IGF-1R might cooperate to endow delE746-A750-mutated PC-9
cells with higher pro-survival signaling in response to erlotinib. To
test this hypothesis, we compared the effects of erlotinib alone or in
combination with I-OMe-AG538, a cell-permeable analog of tyr-
phostin AG538 and potent inhibitor of the IGF-1R kinase activity.
Accordingly, when used in combination with erlotinib, I-OMe-
AG538 was sufficient to sensitize cells to the growth-inhibitory
activity of erlotinib (Fig. 1B). The ability of I-OMe-AG538 to
overcome or circumvent acquired resistance to erlotinib was more
striking in long-term clonogenic assays than short-term MTT assays
(data not shown), indicating that the combinatorial treatment not
only altered the kinetics of cell survival/cell death but also decreased
the number of cells that survived the combination treatment to
subsequently proliferate and form colonies once the co-treatment
ceased. Thus, whereas erlotinib and I-OMe-AG538 as single agents
slightly altered the anchorage-dependent colony-forming ability of
erlotinib-refractory PC-9/ErlR pooled populations, a 3-day con-
current treatment with erlotinib and 10 mmol/L I-OMe-AG538
was sufficient to markedly suppress the frequency of surviving
cells when colony formation was assessed 10 days later (Fig. 1B).
Equivalent results were found when the more specific inhibitor
of IGF-1R AG1024 substituted I-OMe-AG538. Thus, a 10-fold
lower concentration of AG1024 –i.e., 1 mmol/L- was sufficient to
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synergistically circumvent erlotinib-resistance in PC-9/ErlR pooled
populations (Fig. 1B).
The sub-cellular localization of phospho-IGF-1R suggests the
involvement of the epithelial-to-mesenchymal transition (EMT)
phenomenon during the acquisition of resistance to erlotinib. We
evaluated whether enhanced signaling from IGF-1R in erlotinib-
refractory PC-9 pooled populations occurred in distinct sub-
cellular compartments linked to EMT-like features. We performed
high-content immunofluorescence microscopy studies to visualize
sub-cellular accumulation of the active form of IGF-1R using an
antibody against phospho-IGF-1R at Tyr1161 (Fig. 2). Of note, we
observed a striking cell membrane-associated local accumulation of
the active form of IGF-1R in erlotinib-refractory PC-9 pooled
populations but not in erlotinib-responsive PC-9 parental cells
(Fig. 2, top). Examination of phospho-IGF-1RTyr1161 under a higher
magnification revealed that the active form of IGF-1R was distinctly
distributed at the tips of the numerous cell protrusions found in
erlotinib-refractory PC-9 pools (Fig. 2, bottom). Because the sub-
cellular distribution of phospho-IGF-1RTyr1161 indicated a possible
association of IGF-1R with the EMT-like process, we performed
co-staining experiments with antibodies directed against phospho-
IGF-1RTyr1161 and the cytoskeletal protein F-actin (Fig. 2). Erlotinib-
refractory PC-9 cells exhibited a drastic reorganization of the
cytoskeleton compared with erlotinib-sensitive PC-9 parental cells.
Whereas erlotinib-responsive PC-9 cells contained a homogeneous
distribution of F-actin label, a dramatic reorganization of F-actin into
stress fibers that emanated from phospho-IGF-1RTyr1161-positive
focal adhesion-like structures were clearly recognizable in
erlotinib-refractory PC-9/ErlR pooled populations. Thus, most of
erlotinib-refractory PC-9 cells displayed dendritic-like protrusions
with a concentration of F-actin at the phospho-IGF-1RTyr1161-positive
tips. Indeed, co-staining experiments with the cytoskeletal protein
vinculin supported the concentration of phospho-IGF-1RTyr1161 at
the edges of profuse and numerous focal adhesion-like structures
in the cell membrane of PC-9 cells with acquired resistance to
erlotinib (Fig. 3, left).
PC-9 cells with acquired resistance to erlotinib activate an EMT
transcriptional program. The above-mentioned morphological
alterations in erlotinib-refractory PC-9 pooled populations were
compatible with an execution of a genetic program of cells
undergoing EMT, which is defined by the rapid transcriptional
repression of epithelial markers and sustained induction of EMT-
promoting transcription factors. To assess whether EMT-related
morphological changes in the erlotinib-refractory PC-9 pooled
populations were transcriptionally regulated by events directly
controlling the EMT phenomenon, the total RNA from erlotinib-
sensitive PC-9 parental cells and erlotinib-refractory PC-9 cells was
evaluated using a customized array for the quantitative real-time
PCR (qRT-PCR) analysis of 19 genes specifically associated with
EMT and the reciprocal mesenchymal-to-epithelial transition (see
the ‘‘Materials and Methods’’ section for the genes included in the
array). When a two-fold or greater difference in the mRNA
expression level was used as the cut-off to determine significant
regulatory events for the genes involved in the activation and
maintenance of EMT phenomena, erlotinib-refractory PC-9 cells
were found to have significantly increased mRNA levels of a
Figure 1 | Activation of IGF-1R contributes to erlotinib resistance. (A). Phosphoproteome profiling of PC-9 cells before and after acquisition of
resistance to erlotinib. Total cell lysates (750 mg) from PC-9 parental cells before and after adaptation (POOLs) to erlotinib treatment were incubated with
membranes of the phosphoproteomic platform human Phospho-RTK including 42 different RTKs, as per the manufacturer’s instructions (Proteome
Profiler; R&D Systems). Figure shows representative phosphoproteome analyses that were developed on X-ray film following exposure to
chemiluminescent reagents. Equivalent results were obtained in three independent experiments. Of the 42 RTKs analyzed via phospho-arrays, IGF-1R
underwent the highest induction in phosphorylation when comparing erlotinib-refractory PC-9 ErlR pools to erlotinib-sensitive PC-9 parental cells.
(B). Clonogenic survival assay of erlotinib-refractory PC-9/ErlR cells treated with graded concentrations of erlotinib in the absence or presence of the IGF-
1R inhibitors I-Ome-AG538 or AG1024, as specified. Representative photographs show the crystal violet-stained colonies of PC-9/ErlR POOL1 cells given
different treatments either alone or in combination (in duplicate) in a 6-well plate. (Erl: Erlotinib).
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significant subset of EMT-inducing transcription factors (TFs)
(Fig. 3, right). The EMT TFs significantly upregulated in erlotinib-
refractory PC-9 cells included the homeobox protein goosecoid
(GSC), the E-box-binding proteins ZEB1 and ZEB2, the zinc-finger
proteins SNAIL1 and SLUG (SNAIL2), the basis helix-loop-helix
protein TWIST1, and the transmembrane adhesion receptor for
hyaluronan CD44.
In the absence of well-recognized mechanisms of acquired resist-
ance to erlotinib, hyperactive IGF-1R signaling associated with a
drastic enrichment in EMT-related morphological and transcrip-
tional features appears to be sufficient to explain, at least in part,
erlotinib unresponsiveness in the presence of the highly prevalent
erlotinib-sensitizing delE746-A750 EGFR mutation.
Exogenous supplementation with TGFb1 induces an EMT-like
phenomenon in delE746-A750-mutated PC-9 cells. The EMT
gene expression profile was markedly altered in erlotinib-resistant
PC-9 cells with activated IGF-1R compared with erlotinib-
responsive PC-9 parental cells, suggesting that the phenotypic
appearance of erlotinib-refractory PC-9 cell populations is a result
of progressive EMT changes. However, it was unclear whether the
mesenchymal-like cells in the acquired-resistance cancer cell
Figure 2 | Cytoskeleton organization and distribution of the active form of IGF-1R in erlotinib-refractory PC-9 cells. After fixation and
permeabilization, cellular co-distribution of PP-IGF-1RTyr1161 and F-actin was assessed following staining with anti-PP-IGF-1RTyr1161 and anti-F-actin
antibodies, as specified, and Hoechst 33258 for nuclear counterstaining. Images show representative portions of erlotinib-sensitive PC-9 parental cells
and erlotinib-refractory PC-9 POOLs captured in different channels for PP-IGF-1RTyr1161 (green), F-actin (red), and Hoechst 33258 (blue) with a 20 3
objective, and merged on BD Pathway 855 Bioimager System using BD Attovision software.
www.nature.com/scientificreports
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population existed prior to therapy or whether they were induced by
erlotinib treatment. In this scenario, we sought to determine whether
solely inducing EMT in PC-9 parental cells during or before exposure
to erlotinib was sufficient to fully induce a cell phenotype
unresponsive to erlotinib. We first aimed to confirm that
treatment of PC-9 parental cells with the EMT inducer TGFb1 was
sufficient to promote cellular changes (i.e., morphology and size)
resembling those of tumor cells undergoing a bona fide EMT
genetic program. Untreated delE746-A750-mutated PC-9 cells
exhibited a typical epithelial-like morphology. Upon treatment
with TGFb1 (10 ng/mL; 72 h), PC-9 cells acquired a spindle-like
morphology and notably reduced the number of cell-cell contacts
(Fig. 4A, left). EMT-like alterations began after 24 h, and they were
maximal after 72 h, when exposure to TGFb1 fully induced a
complete conversion of parental PC-9 epithelial cells to a
fibroblast-like spindle-shaped elongated PC-9 mesenchymal
morphology. In view of these findings suggesting that exposure to
TGFb1 efficiently triggered cellular changes consistent with EMT
induction in delE746-A750-mutated PC-9 cells, we examined F-
actin reorganization during the mesenchymal-like conversion of
PC-9 lung epithelial cancer cells following TGFb1 administration.
Exogenous TGFb1 supplementation promoted a drastic redefinition
of cell shape and morphology, including a dramatic formation of
long stress fibers of F-actin filaments, which was accompanied by a
noteworthy cytoplasmic accumulation of mesenchymal markers,
such as the intermediate filament vimentin (Fig. 4A, right). These
phenotypic changes were reversed by removal of TGFb1 from the
culture media (data not shown).
The transient induction of mesenchymal-like phenotypes with a
minimal EMT-mRNA/protein signature [SLUG high/E-cadherin
low] is sufficient to induce full refractoriness to erlotinib. We
examined the effects of TGFb1-induced transient EMT on cellular
sensitivity to erlotinib (Fig. 5). PC-9/TGFb1 cells were completely
refractory to the growth inhibitory effects of erlotinib compared with
parental PC-9 cells. Following TGFb1-induced EMT, we failed to
achieve half-maximal effective concentrations of erlotinib in PC-9
cells (Fig. 5). We next asked whether the changes in signaling axes
used in mesenchymal-like PC9 cells with acquired resistance to
erlotinib could be initiated by an EMT-like transition of epithelial
PC9 parental cells simultaneously exposed to erlotinib. Concurrent
exposure of erlotinib-treated cells to TGFb1 notably reduced
erlotinib-induced reduction in PC-9 cell viability (Fig. 5). To
determine whether the EMT-like induced changes in the PC-9/
TGFb1 model might somewhat (early) reflect those observed in
(late) established mesenchymal-like PC-9/ErlR pooled populations,
we measured the expression of the same set of EMT marker genes
using qRT-PCR. When a two-fold or greater difference in the mRNA
expression level was used again as the cut-off to determine significant
EMT-related regulatory effects of short-term exposure to TGFb1, the
PC-9/TGFb1 cells showed significantly increased levels of SLUG
(SNAIL2) (Fig. 4B, left). Because SLUG is a member of the zinc-
finger transcription factor family that binds the E-cadherin
(CDH1) gene promoter region to repress CDH1 transcription
during EMT, it was not entirely unexpected to find that TGFb1-
induced up-regulation of SLUG was accompanied by significantly
reduced transcription of the epithelia-specific gene markers CDH1
Figure 3 | A correlation between IGF-1R activation at focal adhesion-like structures and EMT transcriptomic signatures in erlotinib-refractory PC-9
cells. Left. After fixation and permeabilization, cellular co-distribution of PP-IGF-1RTyr1161 and vinculin was assessed following staining with anti-PP-
IGF-1RTyr1161 and anti-vinculin antibodies, as specified, and Hoechst 33258 for nuclear counterstaining. Images show representative portions of erlotinib-
sensitive PC-9 parental cells and erlotinib-refractory PC-9 POOLs captured in different channels for PP-IGF-1RTyr1161 (green), vinculin (red), and Hoechst
33258 (blue) with a 20 3 objective, and merged on BD Pathway 855 Bioimager System using BD Attovision software. Right. EMT expression profiling of
erlotinib-refractory PC-9 pooled cells versus erlotinib-sensitive PC-9 parental cells. Figure shows a representative scatter plot of the difference in the
relative abundance of 19 mRNAs whose levels, in published results, are significantly altered during activation/deactivation of the EMT genetic program.
Green and red symbols ($ 2-fold) denote downregulation and upregulation versus basal expression in PC-9 parental cells, respectively; grey symbols
denote fold-change results that need to be validated with a sufficient number of biological replicates (i.e., fold-change results may have greater variation of
p value . 0.05 or the p value for the fold-change is either unavailable or relatively high [p . 0.05] or, alternatively, they are uninterpretable because the
gene’s average threshold cycles were either not determined or greater than the defined cut-off value [default 35] in both samples).
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and OCLN (occludin or zonula occludens-1 [ZO-1]). Immunostain-
ing studies confirmed that the expected expression of E-cadherin in
epithelial PC-9 cells was significantly altered in response to TGFb1
treatment (Fig. 4B, right). While the epithelial cell marker E-
cadherin was easily observable in untreated PC-9 control cells,
TGFb1-treated PC9 cells exhibited a drastically altered distribution
of E-cadherin from a conspicuous, highly membranous staining to a
more diffuse, barely detectable cytoplasmic staining.
Transient trans-differentiation to mesenchymal-like phenotypes
through short-term exposure to TGFb1, which activated a minimal
EMT-mRNA/protein signature, including activation of the master
EMT gene SLUG and suppression of the epithelial marker E-cad-
herin, was sufficient to induce unresponsiveness of delE746-A750-
mutated cells to erlotinib.
The induction of an erlotinib-desensitizing EMT phenomenon
proceeds through the activation of IGF-1R. We aimed to explore
whether the induction of EMT might proceed through the activation
of IGF-1R to promote erlotinib refractoriness in the presence of
EGFR exon 19 deletion mutations. Upon TGFb1 treatment, PC-9
likewise flatted and spread very quickly and the morphological
modifications to mesenchymal-like states were not associated with
cell division. A remarkable reorganization of the active form of IGF-
1R at the tips of the prominent F-actin stress fibers was clearly
recognizable during TGFb1-induced EMT in PC-9 cells (Fig 6);
remarkably, the EMT-related re-localization of phospho-active
IGF-1R to EMT-related sub-cellular structures was fully preven-
table when treatment with the EMT inducer TGFb1 was per-
formed in the presence of the IGF-1R inhibitor AG1024 (Fig. 6).
AG1204 concurrently impeded also the TGFb1’s ability to drasti-
cally affect the constant cycling of E-cadherin between the cytoplasm
and the cell membrane to promote that E-cadherin could be inter-
nalized faster than it is readdressed to the membrane; indeed,
the visible loss of cell-cell contacts, the rapid internalization of
Figure 4 | TGFb1 induces a bona fide EMT in erlotinib-sensitive PC-9 cells. (A). PC-9 cells were grown until 75%–80% confluence, serum-starved for
24 h, and then treated for 3 days with 10 ng/mL TGFb1. Phase-contrast (left) and immunofluorescence (right) images were obtained and merged on BD
Pathway 855 Bioimager System according the recommended assay procedure (BD Attovision software). Images show representative portions (n 5 3) of
untreated- or TGFb1-treated PC-9 cells captured in different channels for F-actin (red), vimentin (green), and Hoechst 33258 (blue) with a 20 3 objective.
(B). Left. EMT expression profiling of PC-9/TGFb1 cells versus untreated PC-9 cells. Figure shows a representative scatter plot of the difference in the
relative abundance of 19 mRNAs whose levels, in published results, are significantly altered during activation/deactivation of the EMT genetic program
(see legend in Fig. 3). Right. After fixation and permeabilization, sub-cellular distribution of the epithelial marker E-cadherin was assessed following
staining with an anti-E-cadherin antibody and Hoechst 33258 for nuclear counterstaining. Images show representative portions of untreated- and
TGFb1-treated PC-9 cells captured in different channels for E-cadherin (green) and Hoechst 33258 (blue) with a 20 3 objective, and merged on BD
Pathway 855 Bioimager System using BD Attovision software.
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E-cadherin, and the neo-expression of the mesenchymal-specific
marker vimentin were all prevented by AG1024 (Fig. 6).
Therefore, pharmacological blockade of IGF-1R activity appeared
to spatiotemporally control over the TGFb1-driven pro-EMT
signaling. During TGFb1-induced EMT, we were able to achieve
half-maximal effective concentrations of erlotinib when PC-9/
TGFb1 cells were co-treated with the IGF-1R inhibitor AG1204
(Supplementary Fig. 1).
Short-term exposure to erlotinib is sufficient to enhance IGF-1R-
driven EMT-like features in delE746-A750-mutated PC-9 cells.
Although the above-mentioned findings might support the notion
that TGFb1 and IGF1R function in a linear fashion to drive loss of
responsiveness to erlotinib in delE746-A750-mutated PC-9 cells, the
previously unrecognized ability of erlotinib to converge on the
activation of an IGF-1R-driven EMT phenomenon might also be
considered. We then assessed whether the sole presence of erlo-
tinib was sufficient to activate an IGF-1R-activated/mesenchymal-
like phenotype in delE746-A750-mutated PC-9 epithelial cells.
Intriguingly, short-term exposure to erlotinib significantly impact-
ed on the epithelial morphology of PC-9 cells. After exposure to
erlotinib, PC-9 cells became more loosely arranged and they
Figure 5 | TGFb1-induced EMT is sufficient to promote refractoriness to erlotinib in PC-9 cells. Left panels. The effects of sequential (top) or concurrent
(bottom) treatment with the EMT inducer TGFb1 on cell viability of PC-9 cells exposed to erlotinib were measured by MTT uptake assays. Figure shows
dose-response graphs as% of untreated cell populations (untreated control cells 5 100% cell viability). Results are means (columns) and 95% confidence
intervals (bars) of three independent experiments made in triplicate. Statistically significant differences (one-factor ANOVA analysis) between MTT
uptakes in treated and untreated control cells are shown. Statistical tests were two-sided. Right panels. Images show representative portions (n 5 3) of
control- or TGFb1-treated PC-9 cell cultures at the start of erlotinib treatment (top) or once the treatment with erlotinib is finished (bottom) and captured
in different channels for F-actin (red), vimentin (green), and Hoechst 33258 (blue) with a 20 3 objective, and merged on BD Pathway 855 Bioimager
System using BD Attovision software.
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started to elongate. These changes progressed gradually to a spindle-
shaped morphology, which was evident at , 24 h with erlotinib,
although cells elongated further at 48 h and beyond. Changes in
cell morphology corresponded with partial reorganization of
filamentous actin (F-actin). In untreated PC-9 cells maintained in
the absence of erlotinib, phalloidin-labeled F-actin was likewise
predominantly organized in cortical bundles tightly associated
with cell-cell adhesions. In contrast, after 72 h with erlotinib, F-
actin in subsets of cells was assembled into thick parallel bundles,
or actin stress fibers, traversing the ventral cell surface (Fig. 7). Of
note, the cells showing the most prominent erlotinib-induced
enhancement of stress fibers concurrently exhibited a prominent
re-localization of the phosphorylation of the IGF-1R at the tips of
actin stress fibers. Short-term exposure to erlotinib appeared to
activate a bona fide EMT transcriptional program because
erlotinib-induced dynamic changes in cell morphology and actin
filament organization were accompanied by a gradual decrease in
the abundance of the epithelial cell-cell adhesion protein E-cadherin
and an increase in the abundance of the mesenchymal adhesion
protein vimentin (Fig. 7), as previously shown with TGFb1. We
then explored whether erlotinib treatment was sufficient to activate
IGF-1R at EMT-related sub-cellular localizations and whether
pharmacological inhibition of IGF-1R could prevent erlotinib-
induced EMT in PC-9 cells. The formation of marginal cellular
Figure 6 | Pharmacological inhibition of IGF-1R activity impedes TGFb1-induced EMT in PC-9 cells. PC-9 cells were grown until 75%–80%
confluence, serum-starved for 24 h, and then treated for 3 days with 10 ng/mL TGFb1 in the absence of presence of 1 mmol/L AG1024. Top panels. After
fixation and permeabilization, cellular co-distribution of PP-IGF-1RTyr1161 and F-actin was assessed following staining with anti-PP-IGF-1RTyr1161 and
anti-F-actin antibodies, as specified, and Hoechst 33258 for nuclear counterstaining. Middle panels. After fixation and permeabilization, sub-cellular
distribution of the epithelial marker E-cadherin was assessed following staining with an anti-E-cadherin antibody and Hoechst 33258 for nuclear
counterstaining. Bottom panels. After fixation and permeabilization, sub-cellular distribution of the mesenchymal-specific marker vimentin was assessed
following staining with an anti-vimentin antibody and Hoechst 33258 for nuclear counterstaining. Images show representative portions of untreated-,
TGFb1-, AG1024-, or TGFb1 1 AG1024-treated PC-9 cells captured in different channels for PP-IGF-1RTyr1161 (green), F-actin (red), E-cadherin (green),
vimentin (green), and Hoechst 33258 (blue) with a 20 3 objective, and merged on BD Pathway 855 Bioimager System using BD Attovision software.
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protrusions that stained positively for the active form of IGF-1R at
the tips of the F-actin stress fibers was clearly observable in response
to graded concentrations of erlotinib (Supplementary Fig. 2, top
panels); the EMT-related re-localization of phospho-active IGF-1R
to EMT-related sub-cellular structures was fully preventable when
treatment with erlotinib was performed in the presence of the IGF-
1R inhibitor AG1024. Importantly, the drastic increase in the
abundance of the mesenchymal adhesion protein vimentin
induced in response to erlotinib cannot take place in the presence
of the IGF-1R inhibitor AG1024 (Supplementary Fig. 2, top panels),
thus substantiating that erlotinib-induced EMT-like features took
place through activation of IGF-1R in a linear fashion.
We finally explored the impact of erlotinib treatment on the EMT
phenotype in a NSCLC cell line panel with a well-known profile of
erlotinib responsiveness and the mechanisms involved (Fig. 8).
Similarly to EGFR-mutant PC-9 cells, the expression of E-cadherin
was notably decreased or lost in the positive-control epidermal cell
line, A431, which harbors wild-type EGFR gene amplification, in
response to erlotinib. Unlike PC-9 cells, however, the undetectable
level of the mesenchymal marker vimentin observed in untreated
A431 cells remained unaltered following erlotinib treatment. EGFR
wild-type H460 cells, an erlotinib-refractory mesenchymal cell line,
notably failed to modulate the abundance of the mesenchymal adhe-
sion protein vimentin in response to erlotinib. Immunofluorescence
studies revealed that E-cadherin was associated with disorganized
adhesive structures rather than restricted to the plasma membrane
at areas of cell-cell contact in erlotinib-refractory H1975 cells, which
express both the erlotinib-sensitizing L858R mutation and the
T790M resistant mutation. Interestingly, erlotinib treatment further
enhanced the abnormal distribution of E-cadherin in various cyto-
plasmic locations including cell edges without adjacent cells and
peri-nuclear areas. This lack of E-cadherin staining restricted to areas
of cell-cell contact was accompanied by a conspicuous redefinition of
cell shape and morphology, including a remarkable formation of
long stress fibers of F-actin filaments; accordingly, basal expression
of the mesenchymal marker vimentin was further enhanced in
Figure 7 | Short-term exposure to erlotinib activates EMT-like features in PC-9 cells. PC-9 cells were grown until 75%–80% confluence, serum-starved
for 24 h, and then treated for 72 h with 1 mmol/L erlotinib. Top panels. After fixation and permeabilization, cellular co-distribution of PP-IGF-1RTyr1161
and F-actin was assessed following staining with anti-PP-IGF-1RTyr1161 and anti-F-actin antibodies, as specified, and Hoechst 33258 for nuclear
counterstaining. Middle panels. After fixation and permeabilization, sub-cellular distribution of the epithelial marker E-cadherin was assessed following
staining with an anti-E-cadherin antibody and Hoechst 33258 for nuclear counterstaining. Bottom panels. After fixation and permeabilization, sub-
cellular distribution of the mesenchymal-specific marker vimentin was assessed following staining with an anti-vimentin antibody and Hoechst 33258 for
nuclear counterstaining. Images show representative portions (left panels) or 4 3 4 montages (right panels) of untreated- or erlotinib-treated PC-9 cell
cultures captured in different channels for PP-IGF-1RTyr1161 (green), F-actin (red), E-cadherin (green), vimentin (green), and Hoechst 33258 (blue) with a
20 3 objective, and merged on BD Pathway 855 Bioimager System using BD Attovision software.
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erlotinib-treated H1975 cells. EGFR wild-type H1993 epithelial cells,
which have an amplified MET allele that confers resistance to erlo-
tinib, failed to alter the immunostaining pattern of the tight junc-
tional protein E-cadherin at well-defined cell-cell adhesion com-
plexes in response to treatment with erlotinib.
Discussion
NSCLC tumors carrying EGFR-activating mutations (e.g., exon 19
deletions or L858R) respond preferentially to the EGFR TKIs gefiti-
nib and erlotinib. Despite a dramatic initial response to such inhibi-
tors, over time (median of 6–12 months), most NSCLC patients
develop drug resistance and relapse. Intense research efforts over
the past few years have identified two major mechanisms of acquired
resistance to gefitinib/erlotinib: secondary resistance mutations (e.g.,
T790M) and ‘‘oncogene kinase switch’’ systems (e.g., MET amplifica-
tion and AXL activation). However, the precise mechanisms under-
lying acquired resistance in the 30–40% of EGFR TKI-resistant
EGFR-mutated tumors that do not carry secondary resistance muta-
tions or MET amplification remain largely unclear. Therefore, it is
extremely important to continue to study preclinical models and/or
tumors from NSCLC patients that have developed gefitinib/erlotinib
resistance to uncover novel mechanisms of resistance to EGFR TKIs.
While our current pre-clinical model of delE746-A750-mutated
PC-9 NSCLC cells with acquired resistance to erlotinib apparently
lacked alterations in MET and AXL, our data initially confirmed that
acquired resistance to erlotinib apparently developed through a
‘‘kinase switch’’ mechanism involving IGF-1R RTK hyperactivity.
A noteworthy weakness of our current approach (i.e., erlotinib-res-
istant pooled populations were obtained from lung carcinoma cells
originally harboring an erlotinib-sensitizing EGFR exon 19 deletion)
is that pooled populations may contain cells with varying degrees of
resistance, and the pools developed during this study may harbor
resistance acquired over time or may represent a selected subpopula-
tion of cells with inherent resistance. However, it should be acknowl-
edged that erlotinib-refractory pooled populations better reflect the
heterogeneous alterations that are naturally present in the majority
of tumor cell populations, whereas clones, another possible
approach, represent just one isolated alteration. Nonetheless, in
our current EGFR T790M-, MET-, and AXL-independent scenario
of acquired resistance to erlotinib, the EGFR signaling platform
remained largely intact (i.e., EGFR protein levels remained
unchanged, and the EGFR RTK activity remained active in the
absence or presence of erlotinib), whereas IGF-1R appeared to
assume a prominent role in regulating cell survival during the
development of acquired erlotinib resistance. As a consequence, sim-
ultaneous inhibition of EGFR and IGF-1R activity becomes imper-
ative to overcome erlotinib resistance. Indeed, the fact that the
combination of erlotinib plus IGF-1R inhibitors (I-OMe-AG538 or
AG1024) fully prevents the acquired erlotinib-resistant phenotype is
consistent with IGF-1R playing a major role in this process. While
preparing this manuscript, Cortot et al.31 reported that PC-9-derived
clones with acquired resistance to mutant-selective EGFR inhibitors
and irreversible quinazoline EGFR inhibitors in the absence of EGFR
T790M demonstrate a significantly activated IGF-1R signaling, and
pharmacological inhibition of IGF-1R restored sensitivity to EGFR
inhibitors.
Despite no patient data supporting the role of IGF-1R in acquired
resistance to gefitinib/erlotinib, we are beginning to accumulate evid-
ence from preclinical models indicating that clinical trials of IGF-1R
inhibitors with demonstrated activity in unselected NSCLC patients
might play a role in association with EGFR inhibitors in the man-
agement of NSCLCs with acquired resistance to gefitinib/erloti-
nib32,33. It should be noted that increased IGF-1R activation in
erlotinib-refractory delE746-A750-mutated PC-9 cells occurred in
our lab models independently of changes in IGF-binding proteins
(IGFBPs) (data not shown). Whereas earlier studies have demon-
strated that a loss of IGFBP (IGFBP-3 and IGFBP-4) expression
levels in tumor cells treated with EGFR TKIs activated IGF-1R sig-
naling, which in turn mediated resistance to an EGFR antagonist20,31,
our analyses failed to detect significant changes in the secretion levels
of IGFBPs in delE746-A750-mutated PC-9 cells with acquired resist-
ance to erlotinib. Instead, substantial evidence has related hyperact-
ive IGF-1R signaling with a drastic enrichment in EMT-related
morphological and transcriptional features. Our results suggested
that a mesenchymal status-related activation of IGF-1R was
Figure 8 | Effects of erlotinib treatment on the epithelial/mesenchymal phenotype of NSCLC cells. A431 (positive control), PC-9, H460, H1975, and
H1993 cells were grown until 75%–80% confluence, serum-starved for 24 h, and then treated for 72 h with graded concentrations (1 and 10 mmol/L) of
erlotinib. Left panels. After fixation and permeabilization, sub-cellular distribution of the epithelial marker E-cadherin was assessed following staining
with an anti-E-cadherin antibody and Hoechst 33258 for nuclear counterstaining. Middle panels. After fixation and permeabilization, sub-cellular
distribution of F-actin was assessed following staining with an anti-F-actin antibody and Hoechst 33258 for nuclear counterstaining. Right panels. After
fixation and permeabilization, sub-cellular distribution of the mesenchymal-specific marker vimentin was assessed following staining with an anti-
vimentin antibody and Hoechst 33258 for nuclear counterstaining. Images show representative 4 3 4 montages of untreated- or erlotinib-treated cell
cultures captured in different channels for E-cadherin (green), F-actin (red), vimentin (green), and Hoechst 33258 (blue) with a 20 3 objective, and
merged on BD Pathway 855 Bioimager System using BD Attovision software.
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 3 : 2560 | DOI: 10.1038/srep02560 10
ultimately responsible for conferring resistance to erlotinib to
delE746-A750-mutated PC9 cells. Indeed, our current study suggest
for the first time that NSCLC cells’ intrinsic plasticity to undergo an
IGF-1R/EMT cross-talk in response to erlotinib can sufficiently abol-
ish the erlotinib-sensitizing effect of highly prevalent EGFR muta-
tions. On the one hand, the induction of an EMT phenomenon that
desensitizes delE746-A750-mutated PC-9 cells to erlotinib was found
to proceed, at least in part, through the activation of IGF-1R –i.e.,
TGFb1-induced EMT is accompanied by IGF-1R activation at newly
formed EMT-related sub-cellular structures and the EMT process
triggered by TGFb1 cannot fully occur in the presence of IGF-1R
inhibitors. On the other hand, short-term exposure to erlotinib was
able to potentiate the appearance of EMT-like features in delE746-
A750-mutated PC-9 cells, including stress fibers-associated
activation of IGF-1R. Our data appear to support a previously
unrecognized scenario in which, in the presence of erlotinib-
sensitizing EGFR mutations (delE746-A750, L858R), an aberrant/
incomplete epithelial differentiation might determine the intrinsic
ability of EGFR mutant-NSCLC cells to rapidly shift toward the
erlotinib-refractory mesenchymal end of the epithelial-mesenchy-
mal spectrum. In our hands, acute treatment of EGFR-mutated
PC-9 parental cells with high-dose erlotinib was found to notably
activate an EMT-like phenomenon as part of the transcriptomic
signature associated with erlotinib-induced cell growth inhibition.
Moreover, the fact that erlotinib-enhanced cross-talk between IGF-
1R and EMT signaling pathways was concomitant with a reduction
in PC-9 cell numbers strongly suggests that erlotinib-induced cell
death is not an obligatory outcome of erlotinib treatment in NSCLC
cells harboring erlotinib-sensitizing EGFR exon 19 deletion muta-
tions. The IGF-1R/EMT crosstalk appears to facilitate survival in
erlotinib-naı̈ve delE746-A750-mutated NSCLC cells, likely promot-
ing their own resistance if erlotinib-induced blockade of EGFR per-
sists. If the magnitude and/or duration of induced EMT may
determine the fate of erlotinib-treated EGFR-mutated NSCLC cells
(i.e., EMT is fully induced as a survival mode but fail to rescue
erlotinib-sensitive cells), the intrinsic plasticity of EGFR-mutated
cells to rapidly switch erlotinib-induced EMT as a tumor growth-
inhibitory mechanism to a mechanism of tumor survival may dictate
the likelihood of the duration of erlotinib response. Upon chronic
exposure to erlotinib, therefore, activation of the EMT genetic pro-
gram appears to paradoxically switch from ‘‘growth inhibitory’’ to
‘‘pro-survival’’ in response to erlotinib-induced cell injuries. This
molecular switch might be explained when considering the pre-exist-
ence of IGF-1R-positive EMT-like clones inherently resistant to a
wide variety of tumoricidal insults including erlotinib-induced
blockade of EGFR-driven tumor growth; in this scenario, it could
be hypothesized that chronic exposure to erlotinib negatively select
initially dominant epithelial-sensitive clones and promotes selection
of mesenchymal-refractory tumor clones constitutively harboring an
up-regulated IGF-1R and/or EMT signaling cascade. Alternatively,
thresholds may exist within EGFR-mutated NSCLC cells for the
magnitude of erlotinib-induced EMT that leads to cell death versus
the magnitude of erlotinib-induced EMT that leads to cell survival
and acquired resistance. Indeed, the main inducers of EMT (e.g.,
TGFb) can also promote apoptotic cell death, which suggest that
EMT could potentially serve as a pathway to escape from cell death
depending on the particular microenvironmental milieu. It should be
noted that reduced proliferation has been suggested to be an integral
part of the EMT-induced phenotype that is important for supporting
survival of disseminated metastatic cells. Erlotinib-induced EMT-
related processes to reduce proliferation in favor of enhanced cell
motility and survival, might provide an early selective advantage to
EGFR-mutated NSCLC cells treated with erlotinib. Moreover,
given that EMT can directly generate cancer stem cell cells by directly
linking the acquisition of cellular motility with both the maintenance
of tumor-initiating (stemness) capacity and the acquired
multi-resistance to cancer therapeutics, early suppression of cellular
proliferation by activation of an EMT genetic program may promote
the selective activation of CSC cellular states to lastly generate erlo-
tinib-refractory, CSC-enriched EGFR-mutated NSCLC cell popula-
tions. While further clonal studies are evidently required to
unambiguously uncover the ultimate molecular pathways regulating
the timing between early erlotinib-induced EMT with late EMT-
driven resistance to erlotinib (e.g., it could be relevant to address
whether erlotinib-induced non-viable cells show differential levels
of IGF-1R activation and/or epithelial-mesenchymal features ab
initio), our findings may provide a putative mechanism underlying
the emergence of CSC-like properties in EGFR-mutated NSCLC cells
continuously exposed to high-concentrations of erlotinib.
Dual IGF-1R/EMT-targeting strategies may circumvent acquired
resistance to erlotinib. Combined therapeutic inhibitions of EGFR
and IGF-1R to clinically abrogate this acquired mechanism of drug
resistance in EGFR-mutated NSCLC patients refractory to erlotinib-
based treatments might require the use of EMT markers to ensure a
more responsive patient population prior to the initiation of sub-
sequent lines of therapy. In this regard, it is noteworthy that molecu-
lar analysis of NSCLC responses to IGF-1R inhibition revealed that
intrinsic sensitivity to figitumumab, a monoclonal antibody against
IGF-1R, was significantly related to the simultaneous occurrence of
markers of the IGF-1R pathway in the EMT pathway34. Although it
remains unclear whether high-levels of IGF-1R expression are
directly associated with high IGF-1R kinase activity levels, IGF-1R
is among a small group of oncogenes that can confer in vivo tumor-
igenicity when overexpressed alone via IGFR-1R-mediated induc-
tion of the transcriptional repressor SNAIL and downregulation of
E-cadherin35. Indeed, recent results from our laboratory have con-
firmed that regardless of erlotinib treatment, EMT-enriched erloti-
nib-resistant PC-9 tumor xenografts exhibited a significantly
enhanced tumor engraftment and faster growth compared with erlo-
tinib-sensitive PC-9 parental cells (data not shown). It could be
argued that coupling IGF-1R activation with well-recognized EMT
abilities, such as migration, invasiveness, and metastasis, cannot
explain the enhanced cell survival of EGFR-mutated NSCLC cells
challenged with erlotinib. However, we should acknowledge that
apart from their direct implication in the EMT phenomenon, EMT
transcriptional drivers (e.g., SNAIL factors) can also regulate other
cellular processes related to cell proliferation and survival, thus con-
tributing to resistance to pro-apoptotic stresses36–39. Accordingly, we
recently revealed that a significant reduction in tumor growth and
dramatic gain in sensitivity to the growth-inhibitory effects of the
anti-HER2 monoclonal antibody trastuzumab in vivo can be
observed upon injection of SLUG knocked-down cells into nude
mice40. The promotion of cell survival as a primary function of
EMT factors such as SLUG, which can rescue cells from apoptosis
by repressing pro-apoptotic factors that otherwise would promote
cell death during a partial EMT, is strongly supported by the fact that
exogenous addition of the EMT inducer TGFb1, which efficiently
promoted a transient and reversible trans-differentiation of delE746-
A750-mutated cells to mesenchymal-like phenotypes, was sufficient
to significantly induce refractoriness to the cytotoxic effects of erlo-
tinib. In this regard, it should be noted that E-cadherin appeared to
associate with disorganized adhesive structures in delE746-A750-
mutated PC-9 epithelial cells. Unlike bona fide epithelial cells in
which the localization of E-cadherin is restricted to the plasma mem-
brane at areas of cell-cell contact, E-cadherin was found across the
entire surface of the plasma membrane and was notably distributed
in various cytoplasmic localizations in EGFR-mutated PC-9 cells.
Indeed, E-cadherin staining was notably diffused at areas of cell-cell
contact, and PC-9 cells normally exhibited reduced and punctuated
E-cadherin staining that was not restricted to areas of cell-cell contact
but was also observed along cell edges without adjacent cells. These
findings may suggest that EGFR-mutated NSCLC cells can exhibit a
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‘‘mixed phenotype’’ in which E-cadherin is included in disorganized
adhesive structures that largely lack junctional organization and,
therefore, they might be prompted to rapidly suffer erlotinib-desens-
itizing EMT phenomena in response to certain stimuli including
erlotinib treatment itself. These findings, together with the fact that
exogenous TGFb1 and erlotinib notably cooperate to promote the
acquisition of mesenchymal cell features in erlotinib-naı̈ve PC-9 cell
cultures and the exquisite ability of erlotinib-refractory PC-9/ErlR
pooled populations to further enhance their EMT-associated features
in response to TGFb1 (data not shown), strongly suggest that cross-
talk between TGFb1 and IGF-1R signaling pathways might uncouple
EGFR activity from erlotinib functioning by activating the EMT
phenomenon. Using erlotinib hyper-resistant cells established from
H1650 cells, which are EGFR mutant but unresponsive to erlotinib
due to PTEN deletion, Yao et al41 were pioneers at uncovering the
existence of a TGFb-driven subpopulation of NSCLC cells intrins-
ically resistant to erlotinib that display features suggestive of EMT.
Using the erlotinib-sensitive EGFR mutant NSCLC cell line
HCC4006 harboring the delL747-E749, A750P mutation in EGFR
exon 19, Suda et al.29 established that mesenchymal status, not a
specific oncogenic-activated protein, could sufficiently promote loss
of EGFR dependence to confer resistance to erlotinib. More recently,
Chang et al.42 confirmed that in the absence of the common second-
site EGFR mutation T790M or MET amplification, acquired resist-
ance to gefitinib occurs in EGFR-mutated PC9 cells that have
undergone EMT. In agreement with the above-mentioned pro-sur-
vival role of EMT TFs, the authors observed that SLUG overexpres-
sion efficiently protected PC9 cells from gefitinib-induced apoptosis;
accordingly, specific knockdown of SLUG can reverse secondary
resistance to gefitinib. Importantly, SLUG expression in clinical sam-
ples was significantly higher after the development of acquired res-
istance to EGFR TKIs than in treatment-naı̈ve samples42.
Earlier studies have suggested an active involvement of EMT in
resistance to EGFR TKIs25,27,43,44, and accordingly, E-cadherin
expression has been reported to operate as a biomarker capable of
predicting the clinical efficacy of gefitinib27. However, it should be
noted that these studies were largely based on NSCLC cells expres-
sing wild-type EGFR; therefore, these studies did not mimic clinical
usage of EGFR TKIs because EGFR wild-type NSCLC cells are
intrinsically resistant to EGFR TKIs. We have now confirmed that
acquired resistance to erlotinib in NSCLCs harboring erlotinib-sens-
itizing EGFR mutations could be mediated by EMT induction
through transcriptional reprogramming; the sole activation of a min-
imal EMT-mRNA/protein signature, including upregulation of the
master EMT gene SLUG and suppression of E-cadherin, appeared to
be informative of a significantly reduced responsiveness to erlotinib,
even if transiently activated. In this scenario, it might appear reas-
onable to suggest that in addition to the presence of the T790M
mutation, immunohistochemical and/or microarray-based tran-
scriptional profiling studies dedicated to specific alterations of
EMT drivers (e.g., SLUG) and/or effectors (e.g., vimentin) may be
helpful in monitoring for erlotinib responders and non-responders
based on the loss of biomarkers associated with epithelial status and
gain of biomarkers associated with mesenchymal status. A
microRNA gene expression signature targeting EMT has been
recently shown to predict response to erlotinib45. Byers et al.46
recently developed a robust EMT signature that highlights different
drug responsiveness patterns for epithelial and mesenchymal
NSCLC cells and can predict resistance to EGFR TKIs regardless of
EGFR mutation status. It might be tempting to suggest that such
‘‘mesenchymal transition signatures’’ could be employed as predict-
ive signatures that may merit validation in samples from both com-
pleted and prospective erlotinib-based clinical trials. Erlotinib
therapy-based clinical trials might be designed with predictive
EMT-related marker validation in mind following a rigorous design
because although it is plausible that not all EMT markers included in
a ‘‘mesenchymal transition signature’’ will meet all surrogacy criteria,
their use could provide crucial information on the occurrence of
acquired resistance to erlotinib. We should acknowledge, however,
that a ‘‘mesenchymal transition signature’’ likely reflects a reversible
process in which the mesenchymal markers may dynamically appear
and disappear depending on intrinsic (i.e., cell autonomous) and/or
microenvironmental signals41. Consequently, the potential use of
EMT-like predictive signatures would have high selectively but not
might have the sensitivity to predict acquired resistance to erlotinib.
The presence of the EMT signature in EGFR-mutant tumors would
likely imply inherent or acquired resistance to erlotinib; however,
given the heterogeneity in the mechanisms of acquired resistance, the
lack of the signature in a particular sample from an EGFR mutant-
NSCLC might not indicate erlotinib responsiveness because the sig-
nature may have appeared earlier.
The clinical implications of our data are that erlotinib efficacy in
EGFR-mutant NSCLC patients that have acquired resistance to
EGFR TKIs such as erlotinib might be restored with therapies that
block or reverse the IGF-1R/EMT crosstalk. Specific targeted ther-
apies directed against the cell survival pathways (e.g., IGF-1R) of
mesenchymal-like cells would be predicted to reduce the progression
of EGFR-mutant NSCLCs on erlotinib. In this regard, it is worth
noting that a landmark study showing that the addition of silibinin,
which is the active constituent of silymarin isolated from the dried
fruits of milk thistle (Silybum marianum) plant47–50, to EGFR TKIs
drastically suppresses tumor growth in primary and acquired-resist-
ance cells with the EGFR T790M mutation51 may open a new thera-
peutic avenue to clinically manage EMT-driven acquired resistance
to erlotinib. Silibinin appears to operate as a potent natural agent
leading to the reversal of EMT by decreasing the levels of key EMT
TFs (e.g., SLUG) and increasing the expression levels of E-cad-
herin52–54. Silibinin has been shown to reduce IGF-1R phosphoryla-
tion, indicating an inhibitory effect on the IGF-1R-mediated
signaling pathway in cancer cells55,56. Through using a milk thistle
extract rich in silybin meglumine, a commercially used water-soluble
form of silibinin57, we are currently testing whether the anti-IGF-1R/
EMT activity of silibinin can translate into the reversal of acquired
resistance to EGFR TKIs in animal models. A dual targeting of IGF-
1R and EMT might be crucial to prevent and/or circumvent acquired
resistance to erlotinib in EGFR-mutated cells because, although early
studies by Morgillo et al.58 provided evidence that erlotinib induces
heterodimerization of EGFR/IGF-1R, we failed to observe either co-
localization of the phospho-active forms of EGFR and IGF-1R or
changes in the phosphorylation status of EGFR upon pharmaco-
logical blockade of IGF-1R in EMT-like, erlotinib-refractory pooled
populations (data not shown). Positive anti-IGF-1R/EMT findings
may warrant further clinical evaluation of silibinin derivatives to
effectively delay or prevent the development of acquired resistance
to erlotinib in EGFR-mutant NSCLC patients.
During the preparation of this manuscript, Shien et al.59 reported
that acquired resistance to the EGFR inhibitor gefitinib was assoc-
iated with a manifestation of stem cell-like properties in EGFR-
mutated NSCLC cells, including EMT features, overexpression of
the stem cell-marker aldehyde dehydrogenase (ALDH), increase of
side-population, and self-renewal capacity. Recent findings in our
laboratory have confirmed that erlotinib-refractory PC-9 derivatives
in which hyperactive IGF-1R signaling associates with enrichment in
EMT-related morphological and transcriptional features are simi-
larly enriched with stem-cell like properties and contain drastically
higher percentages (.4,000%) of ALDHbright cells than erlotinib-
responsive parental cells (unpublished observations). While the
majority of previously reported cells that acquired resistance to the
EGFR TKIs gefitinib and erlotinib were established with stepwise
escalation of the EGFR TKI concentration, when Shien et al.59 estab-
lished gefitinib-resistant cells with both the stepwise escalation
method and the high-concentration exposure method, they observed
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that the manner of exposure to the EGFR TKI notable influenced the
mechanism of acquired resistance; in their hands, the emergence of
CSC-like properties solely occurred in response to high-concentra-
tion exposure but not following exposure to very low EGFR TKI
concentrations contributing to the step-wise selection of resistant
cells. It is noteworthy that the high-concentration exposure method
similarly induced EMT features and enrichment of cells with CSC-
like properties in our PC-9 model of acquired resistance to erlotinib.
If cells intrinsically enriched with EMT/CSC-like properties may
exist as minor clones in heterogenous EGFR-mutated NSCLC cell
populations, and they are finally selected as the major clones, both
selection methods would be expected to similarly enrich with EMT/
CSC-like properties the population acquiring resistance to EGFR
TKIs. Although future studies should be designed to unambiguously
clarify whether the high-concentration exposure directly induces the
emergence of EMT/CSC-like properties to mimic a clinically relevant
event, we should acknowledge that our ability to delineate novel
features of resistance to EGFR TKIs in EGFR-mutated NSCLC might
significantly depend on the experimental procedure chosen to select
resistant populations in vitro.
Methods
Cell line. PC-9 NSCLC-derived cells expressing the EGFR exon 19 deletion mutation
(delE746-A750) were obtained from the IBL cell bank (Gunma, Japan). A431, H460,
H1975, and H1993 cell lines were obtained from the American Type Culture
Collection (Manassas, VA, USA).
Generation of PC-9 cells with acquired resistance to erlotinib. To establish EGFR-
mutant NSCLC cells with acquired resistance to erlotinib, cultures of PC-9 NSCLC
cells were continuously exposed to high doses of erlotinib (1 mmol/L) in routine
culture medium, which was replaced every one to two days for approximately two
months. Initially, PC-9 cells numbers were substantially reduced, and for the next 3
months, the surviving cells were passaged in the presence of up to 10 mmol/L erlotinib
approximately every 10–12 days, with a seeding ratio of 152. The cell proliferation
rates slowly increased over the next two months to allow passaging every 5–7 days,
with a seeding ratio of 155. A stable growth rate was reached after a total of 6 months
with routine maintenance of the PC-9/ErlR (erlotinib-resistant) pooled populations
involving passages every 5 days, with a seeding ratio of 1510 of the confluent cell
culture grown in the presence of 10 mmol/L erlotinib.
Drugs and chemicals. The EGFR (HER1) TKI erlotinib (TarcevaH) was a kind gift
from Roche Pharmaceuticals. Stock solutions of erlotinib at 10 mmol/L were
prepared in DMSO and stored in aliquots in the dark at 220uC until utilization.
Recombinant human (carrier-free) TGF-b1 was purchased from R&D Systems Inc.
(Minneapolis, MA). IGF-1R inhibitors I-Ome-AG538 and AG1024 were obtained
from EMD Calbiochem (La Jolla, CA) and dissolved in DMSO at a stock
concentration of 10 mmol/L. For experimental use, all drugs solutions were prepared
fresh from stock solutions and were diluted with cell growth medium. Control cells
were cultured in media containing identical concentrations (v/v) of vehicle.
Phosphoproteome profiling. Erlotinib-sensitive PC-9 parental cells and erlotinib-
refractory PC-9 pooled populations were plated in 100-mm tissue culture dishes and
cultured in regular media containing 10% FBS until they reached 75–80% confluence.
The cells were then washed twice with serum-free medium and incubated overnight
upon serum-free conditions. Cells were then stimulated to grow in 5% FBS-
containing medium in the presence or absence of erlotinib (1 mmol/L for PC-9
parental cells and 10 mmol/L for PC-9 POOLs) for 48 h. Cells were rinsed with cold-
PBS and immediately solubilized in NP-40 lysis buffer [1% NP-40, 20 mmol/L Tris-
HCl (pH 8.0), 137 mmol/L NaCl, 10% glycerol, 2 mmol/L EDTA, 1 mmol/L sodium
orthovanadate, 10 mg/mL aprotinin, 10 mg/mL leupeptin] by rocking the lysates
gently at 4uC for 30 min. Following microcentrifugation at 14,000 3 g for 5 min,
supernatants were transferred into a clean test tube and sample protein
concentrations were determined using the Pierce Protein assay kit (Rockford, IL).
Lysates were diluted and incubated with Human Phospho-RTK Arrays (Proteome
Profiler; R&D Systems; Minneapolis, MN, USA) as per the manufacturer’s
instructions. In this method, capture and control antibodies have been spotted in
duplicate on nitrocellulose membranes. Briefly, the membranes were blocked with 5%
bovine serum album (BSA)/TBS [0.01 mol/L Tris HCl, pH 7.6] for 1 h. Membranes
were then incubated with 750 mg of total protein. After extensive washing with TBS
including 0.1% v/v Tween-20, 3 times for 5 min, to remove unbound materials, the
membranes were then incubated with HRP-phospho-RTK antibodies for 2 h at room
temperature. Unbound HRP antibody was washed out with TBS including 0.1% v/v
Tween-20. Finally, array data were developed on X-ray film using a
chemiluminescence detection system (Amersham Life Sciences).
Cell viability assays. The effect of erlotinib on the cell viability was determined using
a standard colorimetric MTT (3–4, 5-dimethylthiazol-2-yl-2, 5-diphenyl-tetrazolium
bromide) reduction assay. For each treatment, the cell viability was evaluated as a
percentage using the following equation: (OD570 of the treated sample/OD570 of the
untreated sample) 3 100.
Quantitative real-time polymerase chain reaction (qRT-PCR). The total RNA was
extracted from cell cultures using a Qiagen RNeasy kit and QIAshredder columns
according to the manufacturer’s instructions. One microgram of total RNA was
reverse-transcribed to cDNA using the Reaction ReadyTM First Strand cDNA
Synthesis Kit (SABiosciences) and applied to a customized PCR array (96-well
format) containing the following panel of genes: GSC, KRT14, KRT19, NUMB, TCF3,
TCF4, SDC1, ZO-1, CD44, TWIST, SNAI1, VIM, SLUG, CDH1, ZEB1, CDH2, ZEB2,
FN1, and CD24. The arrays were processed according to the SABiosciences RT-PCR
manual and analyzed using an Applied Biosystems 7500 Fast Real-Time PCR System
with an automated baseline and threshold cycle detection. The data were interpreted
using SABiosciences’s web-based PCR array analysis tool.
Immunofluorescence staining and high-content confocal imaging. Cells were
seeded at approximately 5,000 cells/well in 96-well clear-bottom imaging tissue
culture plates (Becton Dickinson Biosciences; San Jose, CA) optimized for automated
imaging applications. TritonH X-100 permeabilization and blocking, primary
antibody staining, secondary antibody staining using Alexa FluorH 488/594 goat anti-
rabbit/mouse IgGs (Invitrogen, Probes, Eugene, Oregon) and counterstaining (using
Hoechst 33258; Invitrogen) were performed following the BD Biosciences protocols.
The images were captured in different channels for Alexa FluorH 488 (pseudocolored
green), Alexa FluorH 594 (pseudocolored red), and Hoechst 33258 (pseudocolored
blue) using a BD PathwayTM 855 Bioimager System (Becton Dickinson Biosciences,
San Jose, California) with 20 3 or 40 3 objectives (NA 075 Olympus). Merged images
were obtained according to the Recommended Assay Procedure using the BD
AttovisionTM software. We employed the following antibodies: 1550 dilution of anti-
PP-IGF-1R (Tyr 1161) (sc-101703; Santa Cruz Biotechnology, Santa Cruz, CA, USA),
1540 dilution of Alexa Fluor 594 Phalloidin (A12381; Invitrogen), 15400 dilution of
anti-vinculin (V9264, clone hVIN-1, Sigma-Aldrich, St. Louis, MO, USA), and 15200
dilution of anti-E-Cadherin (24E10) Rabbit mAb #3195 (Cell Signaling Technology,
Inc., Danvers, MA, USA).
Colony formation. The anchorage-dependent clonogenic growth assay was done by
initially seeding PC-9 parental cells and erlotinib-refractory PC-9 derivatives into
100-mm plates at low density (approximately 3 3 103 cells per well). Cells were either
left untreated or incubated for 72 hours with different concentrations of erlotinib, I-
Ome-AG538, AG1024 or combinations of the two drugs in serum-free RPMI
medium in the presence of IGF (50 ng/mL). Cells were replated in six-well plates and
cultured in drug-free medium for 7 to 10 days, in a humidified atmosphere with 5%
CO2, at 37uC, and then colonies were stained with crystal violet. We then counted the
number of colonies with . 50 cells.
Statistics. Two-group comparisons were performed by the Student t test for paired
and unpaired values. Comparisons of means of $ 3 groups were performed by
ANOVA, and the existence of individual differences, in case of significant F values at
ANOVA, tested by Scheffé’s multiple comparisons. In all the cases statistical analyses
were carried out with XLSTAT (AddinsoftTM) and P , 0.01 was considered to be
significant.
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